Target intelligence / Profile preview

Hydrolethalus syndrome protein 1 (HYLS1)

Target
HYLS1
Molecular classification
Other (centriole and basal body-associated protein critical for ciliogenesis)
01

Overview

Hydrolethalus syndrome protein 1 (HYLS1) is a highly conserved protein localized to centrioles and basal bodies, where it is essential for the formation and proper function of cilia (ciliogenesis)[1][2][3][4]. HYLS1 mediates centriole elongation and recruits key components required for building the ciliary transition fibers and transition zone, thereby regulating the selective gating of proteins into and out of the cilium[1][3][4]. Disruption or mutation of HYLS1 results in severe developmental defects, including hydrolethalus syndrome—a lethal ciliopathy presenting with profound abnormalities in fetal development, particularly brain malformations[1][2][4]. In mammals, HYLS1 has further roles in modulating ciliary signaling, notably the Hedgehog pathway, through interactions with other ciliary proteins such as PIPKIγ and FBF1[2][4]. Although it is a fundamental component required for healthy cell and organismal development, HYLS1 itself is not a direct therapeutic target, and there are no drugs known to interact with it in a clinical context[2][4].

Other names
Centriolar and ciliogenesis-associated protein HYLS1HLSFLJ32915Hydrolethalus syndrome protein 1HLS, centriolar and ciliogenesis-associated protein HYLS1Hydrolethalus syndrome 1
02

Mechanism of action

null

03

Biological functions

Ciliogenesis (formation of cilia)Centriole and basal body function/elongationAssembly and maintenance of the ciliary gate/transition fibers and transition zoneRegulation of protein entry and exit at the cilium (ciliary gating)Modulation of ciliary signaling pathways (including Hedgehog signaling)
04

Disease associations

Other (ciliopathies)Hydrolethalus syndrome (severe, recessive, often lethal developmental disorder)Joubert syndrome (in some cases)
05

Safety considerations

Not applicable; HYLS1 is not a direct therapeutic target and genetic deficiency causes congenital disorder

Beyond the preview

Go deeper on Hydrolethalus syndrome protein 1 (HYLS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hydrolethalus syndrome protein 1 (HYLS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call